98%
921
2 minutes
20
Purpose: The purpose of this study was to test a pharmacist-led intervention to improve gout treatment adherence and outcomes.
Methods: We conducted a site-randomized trial (n=1463 patients) comparing a 1-year, pharmacist-led intervention to usual care in patients with gout initiating allopurinol. The intervention was delivered primarily through automated telephone technology. Co-primary outcomes were the proportion of patients adherent (proportion of days covered ≥0.8) and achieving a serum urate <6.0 mg/dl at 1 year. Outcomes were reassessed at year 2.
Results: Patients who underwent intervention were more likely than patients of usual care to be adherent (50% vs 37%; odds ratio [OR] 1.68; 95% confidence interval [CI] 1.30, 2.17) and reach serum urate goal (30% vs 15%; OR 2.37; 95% CI 1.83, 3.05). In the second year (1 year after the intervention ended), differences were attenuated, remaining significant for urate goal but not for adherence. The intervention was associated with a 6%-16% lower gout flare rate during year 2, but the differences did not reach statistical significance.
Conclusions: A pharmacist-led intervention incorporating automated telephone technology improved adherence and serum urate goal in patients with gout initiating allopurinol. Although this light-touch, low-tech intervention was efficacious, additional efforts are needed to enhance patient engagement in gout management and ultimately to improve outcomes.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6399023 | PMC |
http://dx.doi.org/10.1016/j.amjmed.2018.11.011 | DOI Listing |
J Drugs Dermatol
September 2025
The accumulation of endogenous advanced glycation end products (AGEs) has been shown to degrade the integrity of the extracellular matrix in the dermis, resulting in signs of aging. Resurfacing procedures are a first-line treatment option. Post-procedure skin care is integral in achieving optimal results with minimal downtime.
View Article and Find Full Text PDFInt J Clin Trials
April 2025
Area Brain Aging and Mental Health, New York State Psychiatric Institute, New York, USA.
Background: Cognitive training represents an important potential therapeutic strategy for mild cognitive impairment (MCI). In our recently completed trial, crossword puzzles were superior to computerized cognitive training on Alzheimer's disease assessment scale-cognitive subscale-11 (ADAS-Cog11) and function, correlating with decreased brain atrophy over 78 weeks.
Methods: COGIT-2 is a 78-week, multicenter, clinical trial comparing home-based, high-dose crosswords (4 puzzles per week) to low-dose crosswords (1 puzzle per week) and a health education control group in 240 MCI subjects.
JMIR Res Protoc
August 2025
Khoury College of Computer Sciences, Northeastern University, Boston, MA, United States.
Background: Chronic pain is a debilitating condition that disproportionately impacts US veterans who manage numerous negative pain-related outcomes. There is an urgent need for accessible, engaging, and innovative treatments that can help veterans with chronic pain better self-manage their pain at home and improve their daily functioning. Technology-delivered acceptance- and mindfulness-based interventions for pain have shown strong efficacy, particularly when they are engaging and tailored to specific client needs.
View Article and Find Full Text PDFBackground: Current practice guidelines recommend moderate to vigorous intensity locomotor training to improve walking outcomes in chronic stroke. However, these intensities span a wide range, and the lack of specificity may lead to under-dosing or over-dosing of training intensity. Recent evidence indicates that vigorous intensity locomotor training improves walking outcomes significantly more than moderate intensity.
View Article and Find Full Text PDFFractional dosing of vaccines is a viable strategy to extend COVID-19 vaccine supplies in resource-constrained settings. We did a triple-blinded, multi-site, randomized non-inferiority trial in Nigeria (PACTR202206754734018). Adults 18-65 years received full, half, or quarter primary doses of ChAdOx1 or Ad26.
View Article and Find Full Text PDF